Outcome of vaccinated patients that developed COVID-19 infection
| . | N patients . | % . |
|---|---|---|
| Stay during COVID-19 | ||
| Hospital | 75 | 66.4 |
| COVID-19 ward | 59 | 83.8 |
| ICU | 16 | 14.2 |
| Of which, invasive mechanical ventilation | 10 | 8.8 |
| Home | 38 | 33.6 |
| Overall mortality at 30 d | 14 | 12.4 |
| Attributable to COVID-19 | 9/14 | 64.3 |
| + Hematological malignancy | 3/14 | 21.4 |
| Contributable by COVID-19 | 4/14 | 28.6 |
| + Other reasons* | 2/14 | 14.3 |
| Not related to COVID-19 | 1/14 | 7.1 |
| + Hematological malignancy | 1/14 | 7.1 |
| Mortality according to severity | ||
| Asymptomatic | 1/14 | 7.1 |
| Mild infection | 1/14 | 7.1 |
| Severe infection | 7/14 | 50.0 |
| Critical infection | 5/14 | 35.7 |
| Mortality for stay | ||
| Hospital | 13/14 | 11.5 |
| ICU | 5/14 | 35.7 |
| Of which, invasive mechanical ventilation | 5/5 | 100.0 |
| Home | 1/14 | 7.1 |
| Mortality according to type of vaccine | ||
| BioNTech/Pfizer | 12/79 | 15.2 |
| Moderna COVE | 1/20 | 5.0 |
| AstraZeneca Oxford | 1/10 | 10.0 |
| Sinovac | 0/4 | 0.0 |
| Mortality according to SARS-CoV-2 variant | ||
| WT | 0/14 | 0.0 |
| English: alpha (α) | 4/14 | 28.6 |
| South African: beta (β) | 0/14 | 0.0 |
| Indian: delta (δ) | 0/14 | 0.0 |
| Not tested | 10/14 | 71.4 |
| Mortality according to vaccine scheme | ||
| 1 dose | 4/25 | 28.6 |
| Full dose | 10/78 | 71.4 |
| Mortality according to type of hematological malignancy | ||
| Acute lymphoid leukemia | 0/3 | 0.0 |
| Chronic lymphoid leukemia | 2/28 | 7.1 |
| Acute myeloid leukemia | 0/5 | 0.0 |
| Chronic myeloid leukemia | 0/1 | 0.0 |
| Myelodysplastic syndrome | 2/7 | 28.6 |
| Hodgkin lymphoma | 1/4 | 25.0 |
| Non-Hodgkin lymphoma | 6/36 | 16.7 |
| Myelofibrosis | 1/3 | 33.3 |
| Polycythemia vera | 0/2 | 0.0 |
| Systemic mastocytosis | 1/2 | 50.0 |
| Multiple myeloma | 1/20 | 5.0 |
| Aplastic anemia | 0/2 | 0.0 |
| Mortality for patients with active hematological malignancy | ||
| Yes/no | 7/7 | 50.0/50.0 |
| Mortality for patients with chemo-immuno or radiotherapy | ||
| in the last 3 mo | 10/14 | 71.4 |
| more than 3 mo/w&w | 4/14 | 28.6 |
| . | N patients . | % . |
|---|---|---|
| Stay during COVID-19 | ||
| Hospital | 75 | 66.4 |
| COVID-19 ward | 59 | 83.8 |
| ICU | 16 | 14.2 |
| Of which, invasive mechanical ventilation | 10 | 8.8 |
| Home | 38 | 33.6 |
| Overall mortality at 30 d | 14 | 12.4 |
| Attributable to COVID-19 | 9/14 | 64.3 |
| + Hematological malignancy | 3/14 | 21.4 |
| Contributable by COVID-19 | 4/14 | 28.6 |
| + Other reasons* | 2/14 | 14.3 |
| Not related to COVID-19 | 1/14 | 7.1 |
| + Hematological malignancy | 1/14 | 7.1 |
| Mortality according to severity | ||
| Asymptomatic | 1/14 | 7.1 |
| Mild infection | 1/14 | 7.1 |
| Severe infection | 7/14 | 50.0 |
| Critical infection | 5/14 | 35.7 |
| Mortality for stay | ||
| Hospital | 13/14 | 11.5 |
| ICU | 5/14 | 35.7 |
| Of which, invasive mechanical ventilation | 5/5 | 100.0 |
| Home | 1/14 | 7.1 |
| Mortality according to type of vaccine | ||
| BioNTech/Pfizer | 12/79 | 15.2 |
| Moderna COVE | 1/20 | 5.0 |
| AstraZeneca Oxford | 1/10 | 10.0 |
| Sinovac | 0/4 | 0.0 |
| Mortality according to SARS-CoV-2 variant | ||
| WT | 0/14 | 0.0 |
| English: alpha (α) | 4/14 | 28.6 |
| South African: beta (β) | 0/14 | 0.0 |
| Indian: delta (δ) | 0/14 | 0.0 |
| Not tested | 10/14 | 71.4 |
| Mortality according to vaccine scheme | ||
| 1 dose | 4/25 | 28.6 |
| Full dose | 10/78 | 71.4 |
| Mortality according to type of hematological malignancy | ||
| Acute lymphoid leukemia | 0/3 | 0.0 |
| Chronic lymphoid leukemia | 2/28 | 7.1 |
| Acute myeloid leukemia | 0/5 | 0.0 |
| Chronic myeloid leukemia | 0/1 | 0.0 |
| Myelodysplastic syndrome | 2/7 | 28.6 |
| Hodgkin lymphoma | 1/4 | 25.0 |
| Non-Hodgkin lymphoma | 6/36 | 16.7 |
| Myelofibrosis | 1/3 | 33.3 |
| Polycythemia vera | 0/2 | 0.0 |
| Systemic mastocytosis | 1/2 | 50.0 |
| Multiple myeloma | 1/20 | 5.0 |
| Aplastic anemia | 0/2 | 0.0 |
| Mortality for patients with active hematological malignancy | ||
| Yes/no | 7/7 | 50.0/50.0 |
| Mortality for patients with chemo-immuno or radiotherapy | ||
| in the last 3 mo | 10/14 | 71.4 |
| more than 3 mo/w&w | 4/14 | 28.6 |
alloHSCT, allogeneic hematopoietic stem cell transplantation; COVE, Coronavirus Efficacy and Safety Study; ICU, intensive care unit; w&w, watch and wait.
Renal impairment plus bacterial infection; intestinal subocclusion.